Logo image of TSHA

TAYSHA GENE THERAPIES INC (TSHA) Stock Fundamental Analysis

NASDAQ:TSHA - Nasdaq - US8776191061 - Common Stock - Currency: USD

2.58  +0.17 (+7.05%)

After market: 2.4668 -0.11 (-4.39%)

Fundamental Rating

2

Taking everything into account, TSHA scores 2 out of 10 in our fundamental rating. TSHA was compared to 567 industry peers in the Biotechnology industry. TSHA has a bad profitability rating. Also its financial health evaluation is rather negative. TSHA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TSHA had negative earnings in the past year.
In the past year TSHA has reported a negative cash flow from operations.
In the past 5 years TSHA always reported negative net income.
TSHA had a negative operating cash flow in each of the past 5 years.
TSHA Yearly Net Income VS EBIT VS OCF VS FCFTSHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -55.68%, TSHA is in line with its industry, outperforming 42.76% of the companies in the same industry.
TSHA's Return On Equity of -124.85% is on the low side compared to the rest of the industry. TSHA is outperformed by 60.42% of its industry peers.
Industry RankSector Rank
ROA -55.68%
ROE -124.85%
ROIC N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
TSHA Yearly ROA, ROE, ROICTSHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TSHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSHA Yearly Profit, Operating, Gross MarginsTSHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TSHA has been increased compared to 1 year ago.
The number of shares outstanding for TSHA has been increased compared to 5 years ago.
TSHA has a worse debt/assets ratio than last year.
TSHA Yearly Shares OutstandingTSHA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
TSHA Yearly Total Debt VS Total AssetsTSHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -2.78, we must say that TSHA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.78, TSHA perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
A Debt/Equity ratio of 0.61 indicates that TSHA is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.61, TSHA is doing worse than 75.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Altman-Z -2.78
ROIC/WACCN/A
WACC10.35%
TSHA Yearly LT Debt VS Equity VS FCFTSHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 5.42 indicates that TSHA has no problem at all paying its short term obligations.
The Current ratio of TSHA (5.42) is comparable to the rest of the industry.
TSHA has a Quick Ratio of 5.42. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.42, TSHA is in line with its industry, outperforming 59.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.42
Quick Ratio 5.42
TSHA Yearly Current Assets VS Current LiabilitesTSHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for TSHA have decreased strongly by -376.92% in the last year.
Looking at the last year, TSHA shows a very negative growth in Revenue. The Revenue has decreased by -46.11% in the last year.
EPS 1Y (TTM)-376.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.61%
Revenue 1Y (TTM)-46.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-43.9%

3.2 Future

TSHA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.78% yearly.
Based on estimates for the next years, TSHA will show a very strong growth in Revenue. The Revenue will grow by 119.83% on average per year.
EPS Next Y-4.65%
EPS Next 2Y-11.37%
EPS Next 3Y25.74%
EPS Next 5Y11.78%
Revenue Next Year-18.73%
Revenue Next 2Y-26.73%
Revenue Next 3Y73.22%
Revenue Next 5Y119.83%

3.3 Evolution

TSHA Yearly Revenue VS EstimatesTSHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TSHA Yearly EPS VS EstimatesTSHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TSHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSHA Price Earnings VS Forward Price EarningsTSHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSHA Per share dataTSHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

TSHA's earnings are expected to grow with 25.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.37%
EPS Next 3Y25.74%

More info and screens

0

5. Dividend

5.1 Amount

TSHA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TAYSHA GENE THERAPIES INC

NASDAQ:TSHA (5/2/2025, 8:26:27 PM)

After market: 2.4668 -0.11 (-4.39%)

2.58

+0.17 (+7.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/bmo
Earnings (Next)05-07 2025-05-07/amc
Inst Owners83.26%
Inst Owner Change0%
Ins Owners1.56%
Ins Owner Change6.77%
Market Cap529.03M
Analysts83.53
Price Target6.68 (158.91%)
Short Float %13.82%
Short Ratio11.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.72%
Min EPS beat(2)-5.87%
Max EPS beat(2)17.32%
EPS beat(4)3
Avg EPS beat(4)17.06%
Min EPS beat(4)-5.87%
Max EPS beat(4)46.41%
EPS beat(8)6
Avg EPS beat(8)127.14%
EPS beat(12)8
Avg EPS beat(12)86.39%
EPS beat(16)8
Avg EPS beat(16)58.25%
Revenue beat(2)1
Avg Revenue beat(2)-3.89%
Min Revenue beat(2)-14.14%
Max Revenue beat(2)6.37%
Revenue beat(4)2
Avg Revenue beat(4)-9.06%
Min Revenue beat(4)-59.07%
Max Revenue beat(4)30.59%
Revenue beat(8)6
Avg Revenue beat(8)63.27%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.62%
PT rev (3m)1.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.59%
EPS NY rev (1m)0.52%
EPS NY rev (3m)2.7%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-0.06%
Revenue NY rev (1m)18.8%
Revenue NY rev (3m)34.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 63.49
P/FCF N/A
P/OCF N/A
P/B 7.4
P/tB 7.4
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0.04
BVpS0.35
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.68%
ROE -124.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.04%
Cap/Sales 4.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.42
Quick Ratio 5.42
Altman-Z -2.78
F-Score3
WACC10.35%
ROIC/WACCN/A
Cap/Depr(3y)691.55%
Cap/Depr(5y)1199.42%
Cap/Sales(3y)284.78%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-376.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.61%
EPS Next Y-4.65%
EPS Next 2Y-11.37%
EPS Next 3Y25.74%
EPS Next 5Y11.78%
Revenue 1Y (TTM)-46.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-43.9%
Revenue Next Year-18.73%
Revenue Next 2Y-26.73%
Revenue Next 3Y73.22%
Revenue Next 5Y119.83%
EBIT growth 1Y-21.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.24%
OCF growth 3YN/A
OCF growth 5YN/A